[Only for limited indications. Biventricular pacemaker improves severe heart failure]

Area of Science:

• Cardiology
• Medical Devices
• Electrophysiology

Context:

• Congestive heart failure (CHF) patients often exhibit left ventricular dilatation and dyssynchronous contraction.
• Delayed ventricular conduction, particularly left bundle branch block (LBBB), exacerbates cardiac dysfunction in CHF.
• Current optimal medical therapy may not fully address the mechanical dyssynchrony in advanced CHF.

Purpose:

• To describe biventricular pacing as an emerging non-pharmacological treatment for specific heart failure patients.
• To outline the mechanism of action for biventricular pacing in resynchronizing ventricular contraction.
• To define the initial patient selection criteria for biventricular pacing therapy.

Summary:

• Biventricular pacing involves an implanted electrode system to stimulate the left ventricle, thereby accelerating conduction and resynchronizing contraction.
• This therapy is indicated for patients with stable New York Heart Association (NYHA) stage III heart failure, optimally medicated, and presenting with LBBB and a QRS duration of at least 150 ms.
• The procedure aims to improve cardiac output and alleviate symptoms associated with ventricular dyssynchrony.

Impact:

• Biventricular pacing represents a significant advancement in device-based therapy for heart failure, offering an alternative to or adjunct to drug therapy.
• Successful implementation can lead to improved heart function, reduced hospitalizations, and enhanced quality of life for eligible patients.
• Further data from ongoing randomized mortality studies are crucial for establishing definitive indications and long-term outcomes.